Watch this short video on the three components of breast cancer screening—brought to you by Andrea Porpiglia, MD, MSc, FACS, Assistant Professor, Department of Surgical Oncology at Fox Chase.
Researchers at Fox Chase Cancer Center discuss the benefits of the PARP inhibitor olaparib for women with high-risk, HER2-negative, BRCA-mutant early breast cancer.
Fox Chase Cancer Center is the first cancer center in the Northeast to feature a new tumor marker technology—the EnVisio Surgical Navigation System and SmartClip Soft Tissue Marker technology. This advancement will make breast excisional ...
Recognizing the need for further evaluation of immunotherapy for breast cancer treatment, Fox Chase Cancer Center has opened two investigator-initiated trials exploring the use of immunotherapy for triple-negative and HER2-positive breast cancer.